Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...
Poolbeg Pharma plc - Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology 28 January 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage ...
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported ...
GlobalData on MSN
FDA grants breakthrough status to Biogen’s litifilimab for CLE
The Phase III AMETHYST study is currently assessing litifilimab’s safety and efficacy, with results anticipated in 2027.
Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...
Organized Sports in Teen Girls Linked to Lower Breast Cancer Risk Markers: Study Just 2 hours of weekly organized teen sports ...
Proteins are the molecular machines of cells. They are produced in protein factories called ribosomes based on their ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...
Unraveling the Subtypes and Functional Roles of Dendritic Cells in Cancer Immunity and Immunotherapy
Dendritic cells (DCs) are central players in cancer immunity, serving as the primary link between innate and adaptive immune responses. Their functional ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results